{"schema_version":"secwatch.filing_event.v1","accession":"0000785161-23-000019","form_type":"8-K","ticker":"EHC","cik":"0000785161","company_name":"Encompass Health Corp","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.082872+00:00","generated_at":"2026-06-18T04:04:03.028239+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Encompass Health reiterates FY2023 guidance; Q1 rehab discharge growth strong through February","bullets":["Reaffirms FY2023 net operating revenue guidance of $4.68B-$4.76B and adjusted EBITDA of $860M-$900M.","Reaffirms adjusted EPS guidance of $2.87-$3.16.","Inpatient rehabilitation discharge growth remained strong through February; anticipates seasonal March impact from spring break.","CEO Mark Tarr and CFO Doug Coltharp to participate in Barclays Global Healthcare Conference on March 15."],"urls":{"canonical":"https://secwatch.observer/filing/0000785161-23-000019","json":"https://secwatch.observer/filing/0000785161-23-000019.json","markdown":"https://secwatch.observer/filing/0000785161-23-000019.md","text":"https://secwatch.observer/filing/0000785161-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/785161/000078516123000019/0000785161-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785161/000078516123000019/ehc-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:04:03.028239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}